SMAD4 and pancreatic neoplasm: KRAS mutation, TP53 mutation and CDKN2A deletion were all prognostic factors in patients with pancreatic cancer in TCGA datasets (Figure 1B), while, SMAD4 alteration was not associated with the clinical outcomes of pancreatic cancer patients (Figure 1B).